Securities code: 002675 securities abbreviation: Yantai Dongcheng Biochemicals Co.Ltd(002675) Announcement No.: 2022-005 Yantai Dongcheng Biochemicals Co.Ltd(002675)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete
False records, misleading statements or material omissions.
Special tips:
This performance forecast is the result of the company’s preliminary calculation and has not been audited by an accounting firm. The specific financial data shall be subject to the 2021 annual report disclosed by the company. Please make careful decisions and pay attention to investment risks.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Performance forecast: □ turn loss into profit □ increase in the same direction √ decrease in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 135 million yuan – 170 million yuan
Profit: 417.7658 million yuan, net profit of shareholders decreased by 59.31% – 67.69% over the same period of last year
Profit after deducting non recurring losses: 110 million yuan – 140 million yuan
Profit: 393.54 million yuan. The net profit after profit decreased by 64.43% – 72.05% over the same period of last year
Basic earnings per share: 0.1683 yuan / share – 0.2119 yuan / share; earnings per share: 0.5208 yuan / share
2、 Performance forecast and pre audit
This performance forecast has not been audited by an accounting firm. The company has made pre communication with the accounting firm providing annual audit services for the company on this performance forecast, and there is no significant difference between the two sides on this performance forecast.
3、 Explanation of performance change reasons
(1) Affected by the macro-economy, industrial policies and industrial cycles outside China, combined with the actual operation of the company and other factors, and in accordance with the relevant requirements of the CSRC’s accounting supervision risk tips No. 8 – goodwill impairment, the company made a comprehensive estimation of the operation of all subsidiaries during the reporting period, based on the principle of prudence, In 2021, it is estimated that the provision for goodwill impairment will be about 211 million yuan for the 70% equity asset group of Zhongtai Biological Products Co., Ltd. and the asset portfolio of Yantai Dongcheng Dayang Pharmaceutical Co., Ltd. the final amount of provision for goodwill impairment will be determined after evaluation and audit by the evaluation institution and audit institution with securities and futures qualification hired by the company. (2) At present, a number of diagnosis and treatment products of aprinoia therapeutics Inc. are in the process of R & D, with large R & D investment. The equity method is adopted for the equity investment company of the company. In 2021, due to this investment, the company’s accrued investment income was negative, which further reduced the company’s current net profit.
(3) The increase in the sales cost of API products and the impact of centralized purchase of preparation products led to the decline of operating gross profit margin.
4、 Risk tips
1. This performance forecast is the result of preliminary calculation by the financial department of the company and has not been audited by an accounting firm. 2. This performance forecast is the result of the company’s preliminary calculation, and the specific financial data shall be subject to the 2021 annual report disclosed by the company. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Yantai Dongcheng Biochemicals Co.Ltd(002675) board of directors January 29, 2022
